T1	Value 3 13	= 45 years
T2	Person 14 17	old
R1	Has_value Arg1:T2 Arg2:T1	
T3	Temporal 38 46	previous
T4	Mood 25 34	diagnosis
*	OR T4 T3
T5	Condition 60 82	essential hypertension
T6	Scope 25 46	diagnosis or previous
R2	Has_scope Arg1:T5 Arg2:T6	
T7	Drug 118 140	antihypertensive drugs
T8	Drug 174 196	antihypertensive drugs
T9	Negation 164 167	not
T10	Temporal 197 220	within the last 2 weeks
R3	Has_negation Arg1:T8 Arg2:T9	
R4	Has_temporal Arg1:T8 Arg2:T10	
T11	Multiplier 222 237;266 288	two consecutive at least one day apart
T12	Procedure 299 321	sitting blood pressure
T13	Measurement 381 411	diastolic blood pressure (DBP)
T14	Value 412 420	=90 mmHg
T15	Measurement 424 453	systolic blood pressure (SBP)
T16	Value 454 463	=140 mmHg
R5	Has_value Arg1:T13 Arg2:T14	
R6	Has_value Arg1:T15 Arg2:T16	
*	OR T13 T15
T17	Scope 381 463	diastolic blood pressure (DBP) =90 mmHg or systolic blood pressure (SBP) =140 mmHg
R7	Has_scope Arg1:T12 Arg2:T17	
R8	Has_multiplier Arg1:T12 Arg2:T11	
T18	Temporal 101 110	currently
R9	Has_temporal Arg1:T7 Arg2:T18	
T19	Scope 164 220	not taken antihypertensive drugs within the last 2 weeks
A1	Optional T19
T20	Scope 101 140	currently taking antihypertensive drugs
R10	Subsumes Arg1:T5 Arg2:T20	
T21	Scope 222 463	two consecutive examinations were conducted at least one day apart, and both sitting blood pressure (mean value of 3 measurements) met the following criteria: diastolic blood pressure (DBP) =90 mmHg or systolic blood pressure (SBP) =140 mmHg
T22	Non-representable 464 510	(the second blood pressure was measured at V1)
R12	Has_scope Arg1:T19 Arg2:T21	
*	OR T5 T19
T23	Person 544 549	woman
T24	Observation 553 569	childbearing age
T25	Scope 544 569	woman of childbearing age
A2	Optional T25
T26	Qualifier 591 599	reliable
T27	Observation 600 620	contraceptive method
R11	Has_qualifier Arg1:T27 Arg2:T26	
T28	Temporal 621 637	during the trial
R13	Has_temporal Arg1:T27 Arg2:T28	
T29	Reference_point 628 637	the trial
R14	Has_index Arg1:T28 Arg2:T29	
R15	Has_context Arg1:T25 Arg2:T27	
T30	Mood 575 588	agrees to use
R16	Has_mood Arg1:T27 Arg2:T30	
T31	Observation 676 702	signed an informed consent
T32	Observation 643 667	Voluntarily participates
T33	Procedure 735 762	gene polymorphism detection
T34	Observation 795 817	genotype already known
*	OR T33 T34
T35	Qualifier 783 794	MTHFR C677T
R17	Has_qualifier Arg1:T34 Arg2:T35	
T36	Qualifier 723 734	MTHFR C677T
R18	Has_qualifier Arg1:T33 Arg2:T36	
T37	Condition 844 871	good tolerance to enalapril
T38	Drug 862 871	enalapril
R19	multi Arg1:T37 Arg2:T38	
T39	Measurement 881 910	overall medication compliance
T40	Value 876 880	good
R20	Has_value Arg1:T39 Arg2:T40	
T41	Value 912 916	>80%
R21	Subsumes Arg1:T40 Arg2:T41	
T42	Temporal 938 948	previously
T43	Condition 959 973;988 1001	good tolerance to ACEI drugs
T44	Drug 991 1001	ACEI drugs
R22	multi Arg1:T43 Arg2:T44	
T45	Observation 959 963;978 1001	good adherence to ACEI drugs
R23	multi Arg1:T45 Arg2:T44	
T46	Observation 1014 1032	medication history
T47	Scope 959 1001	good tolerance and adherence to ACEI drugs
R24	Has_temporal Arg1:T47 Arg2:T42	
R25	Has_temporal Arg1:T47 Arg2:T46	
T48	Scope 844 934	good tolerance to enalapril and good overall medication compliance (>80%) in run-in period
*	OR T48 T47
T49	Observation 1050 1088	continues to participate in this study
T50	Qualifier 1038 1049	Voluntarily
R26	Has_qualifier Arg1:T49 Arg2:T50	
